IP Library Granted Patent US 12,337,185
Granted Patent B1
US 12,337,185 · App. 17/148,101 · Granted Jun 24, 2025

Detecting shockable polymorphic ventricular tachycardia

Inventor: Joseph L. Sullivan (Kirkland, WA)
Assignee: West Affum Holdings Designated Activity Company
A61N1/3904A61B5/024A61B5/363A61B5/366
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,337,185
App. No.
17/148,101
Granted
Jun 24, 2025
Kind
B1
Abstract

In one embodiment, a method to diagnose a heart condition by a wearable cardioverter defibrillator is described. The method includes obtaining a signal from the at least one sensor and analyzing the signal from the at least one sensor into usable data. The method including calculating a measured heart rate and a consistency metric from the usable data. The method further including determining when the measured heart rate satisfies a heart rate threshold and determining when the consistency metric satisfies a consistency threshold. The method including diagnosing a slow PVT episode based at least in part on the heart rate threshold and consistency threshold being satisfied.

Claims (66)

1. A method for controlling a wearable cardioverter defibrillator (WCD), the method comprising:

obtaining a signal from at least one sensor, wherein the at least one sensor gathers data about a patient to generate the signal;

analyzing the signal from the at least one sensor into QRS complexes;

determining a width of the QRS complexes;

determining a heart rate from the width of the QRS complexes;

detecting a slow polymorphic ventricular tachycardia (PVT) episode has occurred in the patient based, at least in part, on the heart rate and QRS complexes, the detected slow PVT episode comprises detecting that the heart rate is between 120 and 170 Beats per Minute (BPM) and the QRS complexes are wider than 120 ms;

classifying the slow PVT episode as a delay shock condition or a no shock condition;

detecting whether the delay shock condition has continued for a predetermined period after the slow PVT episode was detected; and

issuing a shock command to the WCD in response to a detection that the delay shock condition has continued for the predetermined period, wherein the shock command causes the WCD to deliver a shock to the patient.

2. The method of claim 1 , further comprising:

not providing any therapy during the predetermined period.

3. The method of claim 1 , further comprising:

calculating a QRS consistency metric for the patient;

comparing a QRS width to the QRS consistency metric; and

calculating a similarity between the QRS width and the QRS consistency metric,

wherein the slow PVT episode is classified as the delay shock condition based on the similarity.

4. The method of claim 1 , wherein the predetermined period is between 5 seconds and 120 seconds.

5. The method of claim 1 , wherein in response to the slow PVT episode being classified as the delay shock condition, the WCD is configured to issue a delay shock command that causes the WCD to wait for the predetermined period prior to delivering the shock to the patient.

6. The method of claim 5 , further comprising:

monitoring the heart rate for the predetermined period; and

wherein the issuing of the shock command is based, at least in part, on the heart rate monitored during the predetermined period.

7. The method of claim 1 , wherein the predetermined period comprises a time period between five seconds and two minutes.

8. A wearable cardioverter defibrillator (WCD) system configured to be worn by a patient, the system comprising:

at least one sensor positioned to gather data about the patient;

one or more memories to store patient data; and

a processor that is communicatively coupled to the at least one sensor and the one or more memories, wherein the processor is configured to:

obtain a signal from the at least one sensor, wherein the signal is generated by the sensor based, at least in part, on the data gathered about the patient;

analyze the signal from the at least one sensor to detect QRS complexes in a heart rhythm of the patient,

determine a width of the QRS complexes,

determine a heart rate from intervals between the QRS complexes,

detect a slow polymorphic ventricular tachycardia (PVT) episode has occurred in the patient based, at least in part, on the heart rate and width of QRS complexes, the detected slow PVT episode comprises detecting that the heart rate is between 120 and 170 Beats Per Minute (BPM) and the widths of QRS complexes are wider than 120 ms,

classify the slow PVT episode as a delay shock condition or a no shock condition; and

in response to a detection that the delay shock condition continued for a predetermined period, issue a shock command to the WCD, wherein the shock command causes the WCD to deliver a shock to the patient.

9. The system of claim 8 , wherein the processor is further configured to:

not provide any therapy during the predetermined period.

10. The system of claim 8 , wherein the processor is further configured to:

calculate a QRS consistency metric for the patient;

compare a QRS width to the QRS consistency metric; and

calculate a similarity between the QRS width and the QRS consistency metric, wherein the slow PVT episode is classified as the delay shock condition based on the similarity.

11. The system of claim 8 , wherein the predetermined period is between 5 seconds and 120 seconds.

12. The system of claim 8 , wherein in response to the slow PVT episode being classified as the delay shock condition, the processor is configured to issue a delay shock command that causes the WCD to wait for the predetermined period prior to delivering the shock to the patient.

13. The system of claim 12 , wherein the processor is further configured to:

monitor the heart rate for the predetermined period; and

wherein the shock command is issued based, at least in part, on the heart rate monitored during the predetermined period.

14. The system of claim 8 , wherein the predetermined period comprises a time period between five seconds and two minutes.

15. A method for controlling a wearable cardioverter defibrillator (WCD), the method comprising:

obtaining a signal from at least one sensor, wherein the at least one sensor gathers data about a patient to generate the signal;

calculating a measured heart rate and a consistency metric from the signal;

determining whether the measured heart rate satisfies a heart rate threshold;

determining whether the consistency metric satisfies a consistency threshold;

detecting a slow polymorphic ventricular tachycardia (PVT) episode has occurred in the patient based at least in part on the heart rate threshold and consistency threshold being satisfied, the detected slow PVT episode comprises detecting that a heart rate is between 120 and 170 Beats Per Minute (BPM) and widths of QRS complexes are wider than 120 ms;

classifying the slow PVT episode as a delay shock condition or a no shock condition based at least in part on the consistency metric;

detecting whether the delay shock condition has continued for a predetermined period after the slow PVT episode was detected; and

issuing a shock command to the WCD in response to detection that the delay shock condition continued for the predetermined period, wherein the shock command causes the WCD to deliver a shock to the patient.

16. The method of claim 15 , further comprising:

monitoring the measured heart rate for the predetermined period; and

selectively canceling the shock of the patient based on the measured heart rate monitored during the predetermined period.

17. The method of claim 15 , wherein the consistency metric is a Supraventricular tachycardia (SVT) discriminator consistency metric for the patient.

18. The method of claim 17 , wherein the consistency metric is determined by:

calculating a SVT discriminator from the signal;

comparing the SVT discriminator to the SVT discriminator consistency metric; and

calculating a similarity between the SVT discriminator and the SVT discriminator consistency metric.

19. The method of claim 15 , further comprising:

not providing any therapy during the predetermined period.

20. The method of claim 15 , wherein in response to the slow PVT episode being classified as the delay shock condition, the WCD is configured to issue a delay shock command that causes the WCD to wait for the predetermined period prior to delivering the shock to the patient.

21. The method of claim 15 , wherein the predetermined period comprises a time period between five seconds and two minutes.

Assignments (4)
SECURITY AGREEMENT Recorded Oct 4, 2023
From: WEST AFFUM HOLDINGS DESIGNATED ACTIVITY COMPANY
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 065116/0049 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2022
From: WEST AFFUM HOLDINGS CORP.
To: WEST AFFUM HOLDINGS DAC
Reel/Frame 060389/0694 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2021
From: KESTRA MEDICAL TECHNOLOGIES, INC.
To: WEST AFFUM HOLDINGS CORP.
Reel/Frame 055493/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2021
From: SULLIVAN, JOSEPH L
To: KESTRA MEDICAL TECHNOLOGIES
Reel/Frame 054909/0058 →
Continuity (1)
Provisional Application 62989668 · Mar 14, 2020
References Cited (190)
US 3724355A · Unger · 1973 [cited by applicant]
US 3724455A · Unger · 1973 [cited by applicant]
US 4583524A · Hutchins · 1986 [cited by applicant]
US 4619265A · Morgan et al. · 1986 [cited by applicant]
US 4666432A · McNeish et al. · 1987 [cited by applicant]
US 4698848A · Buckley · 1987 [cited by applicant]
US 4928690A · Heilman et al. · 1990 [cited by applicant]
US 4955381A · Way et al. · 1990 [cited by applicant]
US 5078134A · Heilman et al. · 1992 [cited by applicant]
US 5228449A · Christ et al. · 1993 [cited by applicant]
US 5348008A · Born et al. · 1994 [cited by applicant]
US 5353793A · Born · 1994 [cited by applicant]
US RE34800E · Hutchins · 1994 [cited by applicant]
US 5394892A · Kenny · 1995 [cited by applicant]
US 5405362A · Kramer et al. · 1995 [cited by applicant]
US 5429593A · Matory · 1995 [cited by applicant]
US 5474574A · Payne et al. · 1995 [cited by applicant]
US 5618208A · Crouse et al. · 1997 [cited by applicant]
US 5662690A · Cole et al. · 1997 [cited by applicant]
US 5708978A · Johnsrud · 1998 [cited by applicant]
US 5741306A · Glegyak et al. · 1998 [cited by applicant]
US 5782878A · Morgan et al. · 1998 [cited by applicant]
US 5792204A · Snell · 1998 [cited by applicant]
US 5902249A · Lyster · 1999 [cited by applicant]
US 5913685A · Hutchins · 1999 [cited by applicant]
US 5944669A · Kaib · 1999 [cited by applicant]
US 6047203A · Sackner et al. · 2000 [cited by applicant]
US 6065154A · Hulings et al. · 2000 [cited by applicant]
US 6108197A · Janik · 2000 [cited by applicant]
US 6148233A · Owen et al. · 2000 [cited by applicant]
US 6201992B1 · Freeman · 2001 [cited by applicant]
US 6263238B1 · Brewer et al. · 2001 [cited by applicant]
US 6280461B1 · Glegyak et al. · 2001 [cited by applicant]
US 6287328B1 · Snyder et al. · 2001 [cited by applicant]
US 6304780B1 · Owen et al. · 2001 [cited by applicant]
US 6319011B1 · Motti et al. · 2001 [cited by applicant]
US 6334070B1 · Nova et al. · 2001 [cited by applicant]
US 6356785B1 · Snyder · 2002 [cited by applicant]
US 6427083B1 · Owen et al. · 2002 [cited by applicant]
US 6437083B1 · Owen et al. · 2002 [cited by applicant]
US 6450942B1 · Lapanashvili et al. · 2002 [cited by applicant]
US 6529875B1 · Nakajima · 2003 [cited by applicant]
US 6546285B1 · Owen et al. · 2003 [cited by applicant]
US 6671545B2 · Fincke · 2003 [cited by applicant]
US 6681003B2 · Linder et al. · 2004 [cited by applicant]
US 6762917B1 · Verbiest et al. · 2004 [cited by applicant]
US 7065401B2 · Worden · 2006 [cited by applicant]
US 7099715B2 · Korzinov et al. · 2006 [cited by applicant]
US 7212850B2 · Prystowsky et al. · 2007 [cited by applicant]
US 7559902B2 · Ting et al. · 2009 [cited by applicant]
US 7587237B2 · Korzinov et al. · 2009 [cited by applicant]
US 7753759B2 · Pintor et al. · 2010 [cited by applicant]
US 7865238B2 · Brink · 2011 [cited by applicant]
US 7870761B2 · Valentine et al. · 2011 [cited by applicant]
US 7894894B2 · Stadler · 2011 [cited by examiner]
US 7907996B2 · Prystowsky et al. · 2011 [cited by applicant]
US 7941207B2 · Korzinov · 2011 [cited by applicant]
US 7974689B2 · Volpe et al. · 2011 [cited by applicant]
US 8135462B2 · Owen et al. · 2012 [cited by applicant]
US 8140154B2 · Donnelly et al. · 2012 [cited by applicant]
US 8369944B2 · Macho et al. · 2013 [cited by applicant]
US 8527028B2 · Kurzweil et al. · 2013 [cited by applicant]
US 8548557B2 · Garstka et al. · 2013 [cited by applicant]
US 8560044B2 · Kurzweil et al. · 2013 [cited by applicant]
US 8615295B2 · Savage et al. · 2013 [cited by applicant]
US 8644925B2 · Volpe et al. · 2014 [cited by applicant]
US 8676313B2 · Volpe et al. · 2014 [cited by applicant]
US 8706255B2 · Phillips et al. · 2014 [cited by applicant]
US 8742349B2 · Urbon et al. · 2014 [cited by applicant]
US 8897860B2 · Volpe et al. · 2014 [cited by applicant]
US 8904214B2 · Volpe et al. · 2014 [cited by applicant]
US 8965500B2 · Macho et al. · 2015 [cited by applicant]
US 9008801B2 · Kaib et al. · 2015 [cited by applicant]
US 9084583B2 · Mazar et al. · 2015 [cited by applicant]
US 9089685B2 · Sullivan et al. · 2015 [cited by applicant]
US 9119547B2 · Cazares et al. · 2015 [cited by applicant]
US 9131901B2 · Volpe et al. · 2015 [cited by applicant]
US 9132267B2 · Kaib · 2015 [cited by applicant]
US 9265432B2 · Warren et al. · 2016 [cited by applicant]
US 9345898B2 · Piha et al. · 2016 [cited by applicant]
US 9408548B2 · Volpe et al. · 2016 [cited by applicant]
US 9445719B2 · Libbus et al. · 2016 [cited by applicant]
US 9454219B2 · Volpe et al. · 2016 [cited by applicant]
US 9579020B2 · Libbus et al. · 2017 [cited by applicant]
US 9592403B2 · Sullivan · 2017 [cited by applicant]
US 9598799B2 · Shoshani et al. · 2017 [cited by applicant]
US 9675804B2 · Whiting et al. · 2017 [cited by applicant]
US 9724008B2 · Sullivan et al. · 2017 [cited by applicant]
US 9878171B2 · Kaib · 2018 [cited by applicant]
US 9895105B2 · Romem · 2018 [cited by applicant]
US 9901741B2 · Chapman et al. · 2018 [cited by applicant]
US RE46926E · Bly et al. · 2018 [cited by applicant]
US 10016613B2 · Kavounas · 2018 [cited by applicant]
US 10076656B2 · Dar et al. · 2018 [cited by applicant]
US 10192387B2 · Brinig et al. · 2019 [cited by applicant]
US 10307133B2 · Kaib · 2019 [cited by applicant]
US 10463867B2 · Kaib et al. · 2019 [cited by applicant]
US 10589110B2 · Oskin et al. · 2020 [cited by applicant]
US 10599814B2 · Landrum et al. · 2020 [cited by applicant]
US 11471693B1 · Sullivan · 2022 [cited by applicant]
US 20020181680A1 · Linder et al. · 2002 [cited by applicant]
US 20030158593A1 · Heilman et al. · 2003 [cited by applicant]
US 20050107833A1 · Freeman et al. · 2005 [cited by applicant]
US 20050107834A1 · Freeman et al. · 2005 [cited by applicant]
US 20060173499A1 · Hampton et al. · 2006 [cited by applicant]
US 20080243201A1 · Bocek · 2008 [cited by examiner]
US 20080312709A1 · Volpe et al. · 2008 [cited by applicant]
US 20090005827A1 · Weintraub et al. · 2009 [cited by applicant]
US 20100007413A1 · Herleikson · 2010 [cited by applicant]
US 20100298899A1 · Donnelly et al. · 2010 [cited by applicant]
US 20110022105A9 · Owen et al. · 2011 [cited by applicant]
US 20110288604A1 · Kaib et al. · 2011 [cited by applicant]
US 20110288605A1 · Kaib et al. · 2011 [cited by applicant]
US 20120112903A1 · Kaib et al. · 2012 [cited by applicant]
US 20120144551A1 · Guldalian · 2012 [cited by applicant]
US 20120150008A1 · Kaib et al. · 2012 [cited by applicant]
US 20120158075A1 · Kaib et al. · 2012 [cited by applicant]
US 20120191476A1 · Reid et al. · 2012 [cited by applicant]
US 20120265265A1 · Razavi et al. · 2012 [cited by applicant]
US 20120283794A1 · Kaib et al. · 2012 [cited by applicant]
US 20120293323A1 · Kaib et al. · 2012 [cited by applicant]
US 20120302860A1 · Volpe et al. · 2012 [cited by applicant]
US 20120310315A1 · Savage et al. · 2012 [cited by applicant]
US 20130085538A1 · Volpe et al. · 2013 [cited by applicant]
US 20130144355A1 · Macho et al. · 2013 [cited by applicant]
US 20130231711A1 · Kaib · 2013 [cited by applicant]
US 20130245388A1 · Rafferty et al. · 2013 [cited by applicant]
US 20130274565A1 · Langer et al. · 2013 [cited by applicant]
US 20130317852A1 · Worrell et al. · 2013 [cited by applicant]
US 20130325078A1 · Whiting et al. · 2013 [cited by applicant]
US 20140012144A1 · Crone · 2014 [cited by applicant]
US 20140025131A1 · Sullivan et al. · 2014 [cited by applicant]
US 20140046391A1 · Cowan et al. · 2014 [cited by applicant]
US 20140070957A1 · Longinotti-Buitoni et al. · 2014 [cited by applicant]
US 20140163663A1 · Poddar et al. · 2014 [cited by applicant]
US 20140324112A1 · Macho et al. · 2014 [cited by applicant]
US 20140378812A1 · Saroka et al. · 2014 [cited by applicant]
US 20150039053A1 · Kaib et al. · 2015 [cited by applicant]
US 20150161554A1 · Sweeney et al. · 2015 [cited by applicant]
US 20150216446A1 · Bukhman · 2015 [cited by examiner]
US 20150297135A1 · Shoshani et al. · 2015 [cited by applicant]
US 20150328472A1 · Sullivan et al. · 2015 [cited by applicant]
US 20160004831A1 · Carlson et al. · 2016 [cited by applicant]
US 20160076175A1 · Rock et al. · 2016 [cited by applicant]
US 20160076176A1 · Rock et al. · 2016 [cited by applicant]
US 20160082277A1 · Foshee, Jr. et al. · 2016 [cited by applicant]
US 20160113581A1 · Amir et al. · 2016 [cited by applicant]
US 20160228718A1 · Koop · 2016 [cited by examiner]
US 20160235998A1 · Warren · 2016 [cited by examiner]
US 20160256104A1 · Romem et al. · 2016 [cited by applicant]
US 20160283900A1 · Johnson et al. · 2016 [cited by applicant]
US 20170014073A1 · Shoshani et al. · 2017 [cited by applicant]
US 20170027469A1 · Amir et al. · 2017 [cited by applicant]
US 20170036066A1 · Chahine · 2017 [cited by applicant]
US 20170040758A1 · Amir et al. · 2017 [cited by applicant]
US 20170162840A1 · Pendry · 2017 [cited by applicant]
US 20170319862A1 · Foshee, Jr. et al. · 2017 [cited by applicant]
US 20170367591A1 · Jorgensen · 2017 [cited by applicant]
US 20180116537A1 · Sullivan et al. · 2018 [cited by applicant]
US 20180117299A1 · Gustavson et al. · 2018 [cited by applicant]
US 20180184933A1 · Sullivan et al. · 2018 [cited by applicant]
US 20180185662A1 · Foshee, Jr. et al. · 2018 [cited by applicant]
US 20180243578A1 · Volosin · 2018 [cited by applicant]
US 20180361165A1 · Jaax et al. · 2018 [cited by applicant]
US 20190030352A1 · Sullivan et al. · 2019 [cited by applicant]
US 20190076666A1 · Medema · 2019 [cited by applicant]
US 20190116896A1 · Armour et al. · 2019 [cited by applicant]
US 20190282823A1 · Freeman · 2019 [cited by examiner]
US 20190321650A1 · Raymond et al. · 2019 [cited by applicant]
US 20190374783A1 · Zhang · 2019 [cited by examiner]
DE 102005060985A1 · 2007 [cited by applicant]
EP 2305110A1 · 2011 [cited by applicant]
JP 4320257B2 · 2009 [cited by applicant]
JP 2014526282A · 2014 [cited by applicant]
JP 5963767B2 · 2016 [cited by applicant]
WO 1998039061A2 · 1998 [cited by applicant]
WO 2011146448A1 · 2011 [cited by applicant]
WO 2012064604A1 · 2012 [cited by applicant]
WO 2012151160A1 · 2012 [cited by applicant]
WO 2015056262A1 · 2015 [cited by applicant]
Keller, Dagmar I. “Wide-complex tachycardia”. Cardiovascular Medicine. 2018; 21(4):90-96 (Year: 2018). [cited by examiner]
Pagan-Carlo, et al., “Encircling Overlapping Multipulse Shock Waveforms for Transthoracic Defibrillation,” JACC Journals, Dec. 1998, vol. 32 Issue 7, p. 2065-2071. [cited by applicant]
The LifeVest Network/Patient Data Management System, Zoll, 2015, 2000503 Rev A. [cited by applicant]
Klein, H. U., Goldenberg I., & Moss, A. J., Risk Stratification for Implantable Cardioverter Defibrillator Therapy: The Role of the Wearable Cardioverter-Defibrillator, Clinical update, European Heart Journal, May 31, 2… [cited by applicant]
LIFECOR LifeVest System Model WCD 3100 Operator's Manual, 2006, PN 20B0040 Rev FI, Zoll Lifecor Corporation, Pittsburgh, PA. [cited by applicant]
LifeVest Model 4000 Patient Manual, Zoll, 2009, PN 20B0047 Rev B. [cited by applicant]
Heartstart MRx and XL AED Algorithm—Application Note, Jul. 2001, Edition 2 Philips Healthcare, USA. [cited by applicant]
The LifeVest Network/Patient Data Management System, Zoll, 2015, 20C0503 Rev A. [cited by applicant]
Zoll, LifeVest, Proven protection from Sudden Cardiac Death, 2017, Pittsburgh PA, USA, 4 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2015/051726, dated May 20, 2016, European Patent Office, Rijswijk, (11 pages). [cited by applicant]